CG Oncology, the pioneering developer of bladder cancer therapeutics goes public on Nasdaq.

CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, goes public on Nasdaq under the ticker CGON. Founded more than a decade ago, CG Oncology team has spend more than a decade to develop and advance novel applications of oncolytic immunotherapy for treating Non-muscle Invasive Bladder Cancer. Camford Capital has been a proud supporter of the company since 2018. More about the company's announcement is here.

Arthur Kuan, Chairman & Chief Executive Officer of CG Oncology